Boardroom Alpha
Boardroom Alpha
ENTX · Additional Proxy Materials (DEFA14A) · Filed June 3, 2026

Entera Bio Ltd — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
June 3, 2026
Ticker
ENTX
Accession
0001178913-26-003081
Boardroom Alpha · Filing insights

Entera Bio's Board urges shareholders to vote FOR all 10 proposals. This includes director elections and changes to compensation and charter provisions.

About Entera Bio Ltd
Market cap
$487M
1Y TSR
+58.6%
3Y TSR
+63.8%
Board grade
B-
Sector
Healthcare
CEO
Miranda Jayne Toledano
Last annual meeting: Jul 14, 2026 · View full Entera Bio Ltd profile →

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
 
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
_______________________________
 
Filed by the Registrant
Filed by a Party other than the Registrant
 
Check the appropriate box:
 
Preliminary Proxy Statement
 
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 
Definitive Proxy Statement
 
Definitive Additional Materials
 
Soliciting Material under §240.14a-12
 
ENTERA BIO LTD.
(Name of Registrant as Specified In Its Charter)
___________________________________________________________
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check all boxes that apply):

 
No fee required.
 
Fee paid previously with preliminary materials
 
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders of
 
ENTERA BIO LTD.
 
To be held on Tuesday, July 14, 2026, 8:00 AM Eastern Time
at Kiryat Hadassah, Minrav Building – Fifth Floor, Jerusalem Israel 9112002
 
COMPANY NUMBER
 
ACCOUNT NUMBER
 
CONTROL NUMBER
 
 
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.
 
If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before June 30, 2026.
 
Please visit www.astproxyportal.com/ast/22270, where the following materials are available for view:
 
Notice of Meeting
 
Proxy Statement
 
Proxy Card
 
Form 10-K
TO REQUEST MATERIAL:
TELEPHONE: 1-888-Proxy-NA (1-888-776-9962) or +1-201-299-6210 (worldwide)
 
E-MAIL: helpAST@equiniti.com
 
WEBSITE: us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials
TO VOTE:
ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. Have your proxy card available when you access the web page.
TELEPHONE: Call toll-free 1-800-PROXIES (1-800-776-9437) in the United States or +1-201-299-4446 worldwide from any touch-tone telephone and follow the instructions. Have your proxy card available when you call.
Vote online or by phone until 11:59 PM Eastern Time the day before the meeting. IN PERSON: You may vote your shares in person by attending the Annual Meeting. MAIL: You may request a card by following the instructions above.
 
1a.
To elect Mr. Sean Ellis as a Class III member of the Board of Directors of the Company (the “Board”) until the 2029 Annual Meeting.
 
1b.
To elect Mr. Steven D. Rubin as a Class III member of the Board until the 2029 Annual Meeting. 1c. To elect Mr. Geno J. Germano as a Class III member of the Board until the 2029 Annual Meeting.
 
2.
To approve the amended compensation terms, as described in the accompanying proxy statement, for the Company’s non-executive directors.
 
3.
To approve share-based compensation, as described in the accompanying proxy statement, for Steven D. Rubin, a Director.
 
4.
To approve share-based compensation, as described in the accompanying proxy statement, for Geno J. Germano, the Chairman of the Board.
 
5.
To approve a one-time grant of compensation, as described in the accompanying proxy statement, for Sean Ellis, a Director.
 
6.
To approve a one-time grant of compensation, as described in the accompanying proxy statement, for Miranda Toledano, the Company’s Chief Executive Officer and a Director.
 
7.
To approve an amendment to the Company's 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares issuable thereunder by 2,500,000 shares, as described in the accom-panying proxy statement and attached as Appendix A thereto.
 
8.
To approve an amendment to the Company’s Amended and Restated Articles of Association to effect an increase in the Company’s authorized share capital, as described in the accompanying proxy statement and attached as Appendix B thereto.
 
9.
To approve, on an advisory, non-binding basis, the compensation paid to the Company’s named executive officers, including the compensation tables and narrative discussion, as described in the accompanying proxy statement.
 
Please note that you cannot use this notice to vote by mail.
10.
To approve the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, or PwC, an independent registered public account-ing firm, as the Company’s independent auditors for the fiscal year ending December 31, 2026, and authorize the Board, (or the Audit Committee, if authorized by the Board) to determine the compen-sation of the auditors in accordance with the volume and nature of their services.
 


 
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH OF PROPOSALS 1-10.
 


 




From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Entera Bio Ltd (ENTX)

Reference

Frequently asked questions

When did Entera Bio Ltd file this DEFA14A?
Entera Bio Ltd (ENTX) filed this Additional Proxy Materials (DEFA14A) with the SEC on June 3, 2026. The accession number assigned by EDGAR is 0001178913-26-003081.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Entera Bio's Board urges shareholders to vote FOR all 10 proposals. This includes director elections and changes to compensation and charter provisions. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Entera Bio Ltd's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Entera Bio Ltd has filed under CIK 1638097, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer